Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.

about

Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward.Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.

P2860

Q42355446-DF9A40C2-E40E-4766-8776-B8441F32847F Q50529551-267C48AB-9D5D-40C0-A00F-A05DC2DF68F1

P2860

Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.

Item

http://www.wikidata.org/entity/Q38193714

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Applications for oncologic dru ...... gs advisory committee reviews.

@en

type

Item

label

Applications for oncologic dru ...... gs advisory committee reviews.

@en

prefLabel

Applications for oncologic dru ...... gs advisory committee reviews.

@en

P1476

Applications for oncologic dru ...... gs advisory committee reviews.

@en

P2093

Bradley J Monk

http://www.w3.org/2001/XMLSchema#string

Daniel S Kapp

http://www.w3.org/2001/XMLSchema#string

Idoroenyi Amanam

http://www.w3.org/2001/XMLSchema#string

John K Chan

http://www.w3.org/2001/XMLSchema#string

Kevin Blansit

http://www.w3.org/2001/XMLSchema#string

Nichole Young-Lin

http://www.w3.org/2001/XMLSchema#string

Tuyen K Kiet

http://www.w3.org/2001/XMLSchema#string

P2860

Drug development cost estimates hard to swallow

The price of innovation: new estimates of drug development costs

Can the pharmaceutical industry reduce attrition rates?

Principles of clinical trial design.

The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.

What is the future of peer review? Why is there fraud in science? Is plagiarism out of control? Why do scientists do bad things? Is it all a case of: "all that is necessary for the triumph of evil is that good men do nothing"?

The FDA's new oncology office.

Progression-free survival as a surrogate endpoint in advanced breast cancer

Speeding up the evaluation of new agents in cancer.

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

P304

299-304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2013-0276

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260558241

http://www.w3.org/2001/XMLSchema#string

P698

24599479

http://www.w3.org/2001/XMLSchema#string

P932

3958455

http://www.w3.org/2001/XMLSchema#string

Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.

about

P2860

P2860

Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932